Michele Rhee

Michele Rhee has extensive experience in advocacy relations and patient engagement. Michele is currently the Head of Global Advocacy Relations and Patient Engagement at Savara Inc. Prior to this, they were the Vice President of Patient Affairs and Advocacy at X4 Pharmaceuticals from 2020 to 2022. From 2017 to 2019, they served as the Head of Patient Affairs at Enzyvant. Michele also held positions at Takeda Oncology, bluebird bio, the National Brain Tumor Society, Health Advances, Cobalt Therapeutics, LLC, Yale Center for Customer Insights, and Yale School of Public Health.

Michele Rhee earned a Bachelor of Arts degree in Spanish from Georgetown University in 2005. Michele then went on to pursue a Master of Public Health degree in Health Policy and Administration from Yale School of Public Health, which they completed in 2010. During the same period, they also obtained an MBA degree from Yale School of Management. Additionally, Rhee attended Phillips Academy Andover from 1997 to 2000.